DavidMichaelSchusterMD

Radiology • Atlanta, GA

Nuclear Cardiology, Nuclear Medicine, Nuclear Radiology

Professor, Radiology & Imaging Sciences, Emory University School of Medicine

Join to view full profile

Dr. Schuster is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schuster's full profile

Already have an account?

Office
Emory University Hospital
1364 Clifton Road, Room E145
Atlanta, GA 30322
Phone+1 404-712-4859

Education & Training

Tufts Medical CenterResidency, Radiology-Diagnostic, 1988 - 1992
Albany Medical CenterInternship, Internal Medicine, 1987 - 1988
Albany Medical CollegeClass of 1987

Certifications & Licensure

GA State Medical License 1996 - 2025
NC State Medical License 1998 - 2025
MA State Medical License 1988 - 1997
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology
American Board of Radiology Nuclear Radiology

Clinical Trials

FACBC PET/CT for Recurrent Prostate Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer Start of enrollment: 2008 Apr 01
Terminated
Phase 2
Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas Start of enrollment: 2012 Aug 01
Completed
Not Applicable
FACBC Outcomes for Post Prostatectomy Start of enrollment: 2012 Sep 01
Completed
Phase 2, Phase 3
FACBC for Recurrent Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
FACBC for Head and Neck Cancers Start of enrollment: 2015 May 01
Withdrawn
Early Phase 1
Fusion Targeted Biopsy of the Prostate Start of enrollment: 2013 Sep 01
Completed
Not Applicable
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer Start of enrollment: 2021 Jul 16
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients With Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy Start of enrollment: 2022 Apr 28
Recruiting
Early Phase 1
Roles: Contact
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes Start of enrollment: 2019 May 10
Active, not recruiting
Phase 2
Roles: Contact
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer Start of enrollment: 2023 Nov 29
Recruiting
Phase 1
Roles: Principal Investigator
F18-MHF: Orthopedic Implants-Associated Infection Detection Start of enrollment: 2024 Jun 01
Not yet recruiting
Roles: Contact, Principal Investigator
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients Start of enrollment: 2024 May 01
Not yet recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

48 citations
PET Tracers Beyond FDG in Prostate Cancer
David M. Schuster, Cristina Nanni, Stefano Fanti
Seminars in Nuclear Medicine. 2016-11-01
79 citations
Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach
Malcolm H. Squires, N. Volkan Adsay, David M. Schuster, Maria C. Russell, Kenneth Cardona
Annals of Surgical Oncology. 2015-03-19
113 citations
Hyperspectral imaging and quantitative analysis for prostate cancer detection.
Hamed Akbari, Luma V. Halig, David M. Schuster, Adeboye O. Osunkoya, Viraj A. Master
Journal of Biomedical Optics. 2012-07-01

Journal Articles

Imaging of Prostate Cancer Using Fluciclovine
David Schuster, MD, ScienceDirect

Authored Content

Y90 Radioembolization Dosimetry Using a Simple Semi-Quantitative Method in Intrahepatic Cholangiocarcinoma: Glass Versus Resin MicrospheresJanuary 2018

Press Mentions

Radiotracer Use Boosts Prostate Cancer OutcomesMay 14th, 2021
Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial Using Advanced Imaging of Prostate Cancer for RadiotherapyMay 30th, 2019
FDA Approves Emory-Developed Prostate Cancer Imaging ProbeJune 1st, 2016
Join now to see all

Grant Support

Anti-[18 F] Facbc PET-CT For Characterization Of Primary Prostate CarcinomaNational Cancer Institute2008–2011
18f-Facbc PET-CT For The Detection And Staging Of Recurrent Prostate CarcinomaNational Cancer Institute2007–2011